# AROA and Mölnlycke Partner to Expand U.S. Access to Endoform™

- Link: https://www.thailand-business-news.com/pr-news/aroa-and-molnlycke-partner-to-expand-u-s-access-to-endoform
- Published: 2026-10-21T07:00:00+07:00
- Author: PR Newswire

|   |

_Exclusive co-promotion agreement combines AROA’s regenerative tissue technology
with Mölnlycke’s wound care expertise and commercial reach_

AUCKLAND, New Zealand, Oct. 21, 2026 /PRNewswire/ — Aroa Biosurgery Limited (ASX:
ARX), a soft tissue regeneration company, has entered into an exclusive agreement
with Mölnlycke Healthcare US to co-promote Endoform™ in U.S. post-acute settings,
effective October 16, 2026.

The agreement combines Endoform and AROA’s proprietary AROA ECM™ technology with
Mölnlycke’s established wound care expertise and commercial reach. It is intended
to bring Endoform to more clinicians and patients and support the product’s continued
growth.

AROA retains ownership of Endoform and AROA ECM technology and will continue to 
manufacture, distribute and supply the product. The arrangement also allows AROA
to focus its resources on growing Myriad™ adoption in surgical settings and pursuing
the opportunity for Symphony™ in outpatient wound care.

"We welcome the opportunity to partner with Mölnlycke, a well-established advanced
wound care business known for excellence," said Brian Ward, AROA Founder and CEO."
Mölnlycke’s deep expertise in wound care and broad commercial footprint provide 
a strong platform to bring Endoform to more clinicians and patients.

"This arrangement also allows us to concentrate our efforts on AROA’s strategic 
priorities — sustaining Myriad’s growth and pursuing the significant opportunity
for Symphony, while continuing to manufacture and supply Endoform."

"Improving wound care requires strong partnerships and continued innovation," said
Craig Kennedy, Mölnlycke VP Americas. "Our collaboration with AROA reflects a shared
commitment to advancing clinical practice, supporting healthcare professionals, 
and improving patient outcomes. By adding Endoform to our advanced wound dressing
portfolio, we’re expanding the solutions available to clinicians and addressing 
the diverse needs of the patients they serve."

The agreement relates solely to Endoform in U.S. post-acute settings. AROA’s other
product portfolios and commercial arrangements, including Endoform distribution 
outside the United States, remain unchanged.

AROA’s FY27 financial guidance remains unchanged at NZ$115–125 million in total 
revenue and NZ$8–11 million in normalized EBITDA.*

**About Endoform**

Endoform products are extracellular matrix products composed of AROA ECM, for the
management of acute and chronic wounds in outpatient or post-acute settings.

**About AROA Biosurgery**

Aroa Biosurgery Limited (ASX: ARX) is a New Zealand-based soft tissue regeneration
company developing and commercializing products for complex wounds and soft tissue
reconstruction. Its products incorporate proprietary AROA ECM technology. For more
information, visit [www.aroa.com](https://aroa.com/).

**About Mölnlycke**

Mölnlycke Health Care is a world-leading MedTech company specializing in innovative
solutions for wound care and surgical procedures. Mölnlycke products and solutions
are used daily by hospitals, health care providers and patients in over 100 countries
around the world. Founded in 1849, Mölnlycke is owned by Patricia Industries, part
of Investor AB, and is headquartered in Sweden. [www.molnlycke.com](https://www.molnlycke.com/en-us/?utm_source=press_release&utm_medium=pr&utm_campaign=Aroa_partnership).

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [AROA and Mölnlycke Partner to Expand U.S. Access to Endoform™ ](http://www.prnasia.com/story/archive/5076358_CN76358_0?rand=184833)